VENLAFAXINE XR CAPSULE (EXTENDED RELEASE)

Quốc gia: Canada

Ngôn ngữ: Tiếng Anh

Nguồn: Health Canada

Thành phần hoạt chất:

VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE)

Sẵn có từ:

RANBAXY PHARMACEUTICALS CANADA INC.

Mã ATC:

N06AX16

INN (Tên quốc tế):

VENLAFAXINE

Liều dùng:

37.5MG

Dạng dược phẩm:

CAPSULE (EXTENDED RELEASE)

Thành phần:

VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 37.5MG

Tuyến hành chính:

ORAL

Các đơn vị trong gói:

30

Loại thuốc theo toa:

Prescription

Khu trị liệu:

SELECTIVE SEROTONIN AND NOREPINEPHRINE-REUPTAKE INHIBITORS

Tóm tắt sản phẩm:

Active ingredient group (AIG) number: 0131294002; AHFS:

Tình trạng ủy quyền:

APPROVED

Ngày ủy quyền:

2012-08-16

Đặc tính sản phẩm

_ _
_ _
_VENLAFAXINE XR (venlafaxine hydrochloride extended-release capsules)
_
_Page 1 of 62_
PRODUCT MONOGRAPH
PR
VENLAFAXINE XR
(VENLAFAXINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULES)
37.5, 75 AND 150 MG
VENLAFAXINE (AS VENLAFAXINE HYDROCHLORIDE)
Professed Standard
ANTIDEPRESSANT/ANXIOLYTIC
Ranbaxy Pharmaceuticals Canada Inc.
2680 Matheson Blvd. East, Suite 200 Date of Preparation: August 14,
2012
Mississauga, Ontario
Canada L4W 0A5
Submission Control No: 156578
_ _
_ _
_VENLAFAXINE XR (venlafaxine hydrochloride extended-release capsules)
_
_Page 2 of 62_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
17
DRUG INTERACTIONS
.........................................................................................................
31
DOSAGE AND ADMINISTRATION
.....................................................................................
36
OVERDOSAGE
.......................................................................................................................
40
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 41
STORAGE AND STABILITY
.................................................................................................
45
SPECIAL HANDLING INSTRUCTIONS
..............................................................................
45
DOSAGE FORMS, COMPOSITION AND PACKAGING
..............